Psyence Biomedical
5 hedge funds and large institutions have $718K invested in Psyence Biomedical in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.93% more ownership
Funds ownership: 9.39% → 10.32% (+0.93%)
6% less capital invested
Capital invested by funds: $764K → $718K (-$45.3K)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$63.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.4K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$17.2K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$14.4K |
PBM Hedge Fund Activity: Q4 2025 in Review
5 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q4 2025, worth a combined $718K — down 5.9% from $764K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PBM and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Virtu Financial, adding an estimated $63.7K. The largest seller was AdvisorShares Investments, exiting entirely with an estimated $17.2K sold.
- 5 institutional investors held Psyence Biomedical (PBM) as of Q4 2025, down from 6 in Q3 2025.
- Funds reported $718K of Psyence Biomedical stock for Q4 2025, down 5.9% quarter-over-quarter.
- 1 fund opened new Psyence Biomedical positions in Q4 2025 and 2 closed out, a net change of -1 holder.
- The largest Psyence Biomedical buyer in Q4 2025 was Virtu Financial, an estimated $63.7K added.
- The largest Psyence Biomedical seller in Q4 2025 was AdvisorShares Investments, an estimated $17.2K sold.
Based on aggregated 13F filings for Q4 2025.